Legal Representation
Attorney
James R. Meyer
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 10, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 10, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Sep 24, 2004 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Sep 7, 2004 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Sep 7, 2004 | I | PAPER RECEIVED | Loading... | |
| Jul 21, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| Mar 2, 2004 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Mar 2, 2004 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Mar 4, 2004 | I | PAPER RECEIVED | Loading... | |
| Aug 29, 2003 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Aug 29, 2003 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 29, 2003 | I | PAPER RECEIVED | Loading... | |
| May 8, 2003 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Mar 24, 2003 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 9, 2003 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Mar 24, 2003 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Mar 24, 2003 | I | PAPER RECEIVED | Loading... | |
| May 2, 2002 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 2, 2002 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 26, 2002 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 1, 2002 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 12, 2001 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Oct 2, 2001 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 30, 2001 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 16, 2001 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Jan 3, 2001 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
House mark for a line of pharmaceutical products for the treatment of diabetes, cardiovascular diseases, neurological diseases, psychiatric diseases, infectious diseases, cancer, endocrine diseases, gastrointestinal diseases, viral diseases and immune system enhancers
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005